The risk of upper gastrointestinal (GI) adverse events of patients switching from risedronate to alendronate after the introduction of generic alendronate products in the UK

S. H. Ralston, T. D. Kou, B. C. Wick-Urban, M. Steinbuch

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)S114-S115
Number of pages2
JournalBone
Volume44
DOIs
Publication statusPublished - May 2009

Cite this